Shenzhen Jianyuan Pharmaceutical Technology Co., LTD. (hereinafter referred to as: Jianyuan Pharmaceutical), founded in 2009, is an innovative pharmaceutical enterprise with independent intellectual property rights integrating research and development, production and sales of peptide drugs. The company has two wholly-owned subsidiaries, Shenzhen Jianxiang Biopharmaceutical Co., LTD and Hubei Jianxiang Biopharmaceutical Co., LTD. The company has established a technology platform for the research and development of natural product precursor drugs and polypeptide and protein drug slow-release preparations with known targets in China.
In 2010, Star Silver Investment Group controlled Jianyuan Pharmaceutical, and thus entered the stage of rapid development. In the development, Jianyuan Pharmaceutical has established long-term cooperative relations with many universities and research institutes at home and abroad, and has a high-quality project management, research and development and marketing team and professional expert consultant team. The company has a 1000m2 R&D center in the bio-incubator of Shenzhen High-tech Zone; R&d center has a complete drug research and development system, equipped with advanced instruments and equipment, such as high performance liquid chromatograph, preparation chromatograph, mass spectrometer, gas chromatograph, ion chromatograph, and slow release microspheres pilot production line. At the same time, a new drug development and research platform of about 3800 m2 in line with the requirements of the engineering technology center has been built in the Pingshan New District bioaccelerator.
Jianyuan Pharmaceutical currently has two production sites. In the Xingyin Pharmaceutical Industrial Park located in Lishui, Nanjing, there are four production lines of peptide apis that meet the requirements of the US FDA. Some peptide products are exported to mainstream drug markets such as Europe and America. At the Bioaccelerator in Pingshan New District, Shenzhen, two production lines have been built that meet the requirements of GMP, mainly producing card-type bottle injections, small-capacity injections and freeze-dried powder injections. In addition, more than 300 mu of land was purchased in Xianan Economic Development Zone, Hubei Province, for the construction of a new industrial production base of polypeptide drugs that meets the US FDA, EU and Chinese GMP standards.
In recent years, Jianyuan Medicine has been identified as "Shenzhen high-tech enterprise" and "National high-tech enterprise", Jianyuan will, as always, rely on excellent entrepreneurs, lead professional staff, through accurate market positioning and the implementation of scientific marketing strategy, continue to carry out scientific and technological innovation and management innovation. By means of information management, Jianyuan Pharmaceutical formulates strict quality control system and perfect comprehensive management, laying a good foundation for the sustainable development of the company. Adhering to the enterprise spirit of "integrity, responsibility, efficiency and cooperation", Jianyuan Pharmaceutical will be committed to becoming an influential and innovative enterprise in the pharmaceutical industry, and will also make unremitting efforts to provide trustworthy pharmaceutical products for human health!